3.07
Quantum Biopharma Ltd stock is traded at $3.07, with a volume of 207.87K.
It is up +1.66% in the last 24 hours and up +23.79% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$3.02
Open:
$2.97
24h Volume:
207.87K
Relative Volume:
0.71
Market Cap:
$17.90M
Revenue:
-
Net Income/Loss:
$-26.96M
P/E Ratio:
-0.3526
EPS:
-8.7061
Net Cash Flow:
$-8.25M
1W Performance:
-16.58%
1M Performance:
+23.79%
6M Performance:
-59.47%
1Y Performance:
-2.54%
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
QNTM
Quantum Biopharma Ltd
|
3.07 | 17.90M | 0 | -26.96M | -8.25M | -8.7061 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum Biopharma buys additional $1 million of Bitcoin, other cryptocurrencies - MSN
Quantum BioPharma announces private placement - MSN
Press Releases about Royal Bank of Canada (Toronto Stock Exchange:RY) - FinancialContent
Value Recap: Should I invest in Quantum BioPharma Ltd before earnings2026 News Drivers & Technical Buy Zone Confirmation - baoquankhu1.vn
Operating expenses (excl. COGS) of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAM:0K91 - TradingView — Track All Markets
QNTM Should I Buy - Intellectia AI
Whats the fair value of Quantum BioPharma Ltd stockWeekly Gains Report & Risk Managed Investment Entry Signals - baoquankhu1.vn
Recap Report: Can Quantum BioPharma Ltd generate free cash flow2026 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements - ACCESS Newswire
Top Cannabis Stocks To Watch NowApril 4th - MarketBeat
QNTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Quantum BioPharma Ltd. (QNTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Quantum BioPharma Ltd. (QNTM) stock price, news, quote and history - Yahoo Finance UK
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied - Sahm
Quantum Biopharma Ltd. (QNTM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cannabis Stocks To Watch TodayApril 2nd - MarketBeat
Quantum BioPharma Cleared to Proceed With $700 Million Market Manipulation Lawsuit After Motion to Dismiss Largely Denied - TipRanks
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma submits IND application for MS drug candidate By Investing.com - Investing.com South Africa
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - Sahm
Quantum BioPharma (QNTM) Files FDA Application for New MS Drug - GuruFocus
Promising Cannabis Stocks To Follow TodayApril 1st - MarketBeat
Quantum BioPharma up 5% as Submits IND Application For Lucid-MS - marketscreener.com
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis - TipRanks
Quantum BioPharma submits investigational new drug (IND) application to United States Food and Drug Administration (FDA) - marketscreener.com
Quantum BioPharma submits IND application for MS drug candidate - Investing.com
Quantum BioPharma (QNTM) advances Lucid-MS with FDA IND for Phase 2 MS trial - Stock Titan
BioPharma Spoofing Suit Against Canadian Banks Proceeds - Law360
Top Cannabis Stocks To Keep An Eye OnMarch 31st - MarketBeat
Quantum BioPharma partners with Allucent for MS drug trial By Investing.com - Investing.com South Africa
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclero - GuruFocus
Quantum BioPharma (QNTM) Partners with Allucent for Lucid-MS Pha - GuruFocus
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclerosis Treatment - GuruFocus
Quantum BioPharma signs binding letter of intent with Allucent to conduct Phase 2 clinical trial in Multiple Sclerosis - marketscreener.com
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS - tipranks.com
Quantum BioPharma And Allucent Enter Binding Letter Of Intent For Phase 2 Clinical Trial In Multiple Sclerosis - marketscreener.com
Quantum BioPharma partners with Allucent for MS drug trial - Investing.com
Quantum BioPharma Partners with Allucent to Advance Phase 2 Clinical Trial of Lucid-MS for Multiple Sclerosis Treatment - Quiver Quantitative
Quantum BioPharma (QNTM) lines up Allucent for Lucid-MS Phase 2 trial - Stock Titan
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis - GlobeNewswire
Portfolio Recap: Will Quantum BioPharma Ltd stock benefit from M A2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push - TipRanks
Quantum BioPharma Ltd.: Fundamental Analysis and Financial Ratings | 0K91 | CA74764Y2050 - marketscreener.com
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):